Figure 2

Proliferative pathways are activated in CD97-expressing patient glioblastoma cells and are suppressed with CD97 knockdown in a human GBM cell line. Proliferative pathways are activated in CD97-expressing patient GBM cells (A–D). (A) Variable feature plots illustrating the top 10 differentially expressed genes in CD97⁺ cells versus CD97^- cells demonstrate a bias toward NFKB pathway in CD97⁺ cells and higher expression of immune genes in CD97^- cells. (B) Genes associated with NFKB signaling were upregulated in CD97⁺ cells compared to CD97^- cells. (C) CD97 + tumor cells had higher expression of several receptors that utilize PI3K/Akt signaling, cytoplasmic activators of Akt, and downstream targets of Akt. (D) CD97⁺ tumor cells had higher expression of genes associated with the MAPK pathway activity score (MPAS) than CD97^- tumor cells. (E) CD97⁺ tumor cells had higher expression of genes associated with GBM stem cells than CD97^- tumor cells. (F) WT U251 cells demonstrate higher protein expression of phosphorylated AKT (pAKT) compared to CD97KO U251 cells (P < 0.01), while AKT, ERK, and phosphorylated ERK (pERK) did not demonstrate difference in protein expression between the two groups. Full western blots are shown in Supplementary Figs. S12 and S13. *P < 0.05, **P < 0.01, ***P < 0.001.